NOTES


W50

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 / Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 - 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 - 3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study.(NASDAQ:DBVT)

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS (NASDAQ:BCTX)

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival. (NASDAQ:CADL)

Metagenomi shared closed after an analyst report from Jefferies, which assigned a 'Buy' rating and set a price target of $21, indicating a potential upside of over 1,000%. The report highlights Metagenomi's advancements in gene editing, particularly the durable Factor VIII activity levels achieved in non-human primate studies for their hemophilia A treatment, MGX-001. Additionally, the company's collaborations, such as with Ionis Pharmaceuticals on RNA-targeted therapeutics, further bolster investor confidence. (NASDAQ:MGX)

Chimerix announced plans to submit a New Drug Application (NDA) for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma, before year-end following collaborative discussions with the FDA. If approved, dordaviprone would be the first therapy for this aggressive brain cancer, with potential U.S. launch as early as 3Q 2025. Clinical data highlighted a 28% objective response rate, median response duration of 10.4 months, and significant reduction of the hallmark mutation. A Priority Review request is also planned, which could expedite the FDA review process. (NASDAQ:CMRX)

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial (NASDAQ:SONN)

LeddarTech Announces Collaboration with Texas Instruments for Advanced Driver Assistance Systems and Autonomous Driving Solutions (NASDAQ:LDTC)


W49

Protara Therapeutics reported positive Phase 2 results for TARA-002 in NMIBC, achieving a 72% six-month complete response rate, 100% CR in BCG-unresponsive patients, and no severe adverse events, with durable responses up to six months; 12-month data anticipated mid-2025. Shares closed the week up 96% at $5.91. (NASDAQ:TARA)

Senti Biosciences, Inc. reported initial Phase 1 data for SENTI-202 in relapsed/refractory hematologic malignancies, with 2 of 3 patients achieving MRD-negative CR and a favorable safety profile, while raising $16.7M via a PIPE deal through Series A Convertible Preferred Stock. Shares closed the week up 156% at $5.5. (NASDAQ:SNTI)

Maxim Group analyst Michael Okunewitch initiates coverage on Citius Oncology with a Buy rating and announces Price Target of $3. (NASDAQ:CTOR)

Shimmick awarded $45.4M contract to complete Murray Street Bridge project. (NASDAQ:SHIM)

Janux Therapeutics announced positive updated interim clinical data for its JANX007 clinical program. "These clinical data show substantial. (NASDAQ:JANX)

Cheetah Net Supply Chain Service Inc. today announced that it has executed definitive agreements for the acquisition of TW & EW Services Inc, a California-based labor and logistics service provider ("TW & EW"). The Acquisition is expected to close on or about December 4, 2024. With TW & EW's integration, Cheetah expects to capitalize on additional service opportunities, and strengthen its position as a comprehensive supply chain solutions provider. The total cost of the Acquisition includes a cash payment of $200,000 and a share consideration involving the issuance of Cheetah's unregistered Class A common stock valued at $800,000, with a per-share price at $1.704. Following the Acquisition, TW & EW will become a wholly owned subsidiary of the Company.(NASDAQ:CTNT)

U.S. announces new export controls on China's chip industry. /pdf/

Nauticus Robotics, Inc., a leading innovator in autonomous subsea robotics and software, recently completed a project for a second global supermajor oil and gas company in the Gulf of Mexico (GOM) to perform a subsea field inspection utilizing its flagship underwater vehicle, Aquanaut Mark 2. (NASDAQ:KITT)

Shares of semiconductor companies are trading higher. The Biden administration plans on limiting China's access to advanced chips, chipmaking tools and memory technology due to alleged national security concerns and AI's military potential. - ARM ADI AMAT AMD ASML AVGO ENPH FORM GFS ICHR JKS KLAC LAES LRCX MCHP MPWR NVTS NXPI ON QCOM SPI SQNS TER TSM WOLF - The outgoing Biden administration will implement its third crackdown on China's semiconductor industry within three years, citing the same national security threats as reasons it mentioned for its prior sanctions, intensifying geopolitical tensions between the countries. The initiative, launching Monday, will impose export restrictions on 140 Chinese entities, including chip equipment manufacturers such as Naura Technology Group and other firms, targeting advanced memory chips and chipmaking tools. Nvidia Corp stock is trading lower on Monday. Prior reports indicated Nvidia's potential to earn $12 billion in sales from 1 million H20 GPUs in China in 2024.

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer.(NASDAQ:PPBT)

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML. Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing. (NASDAQ:SNTI)